

Somapacitan for treating growth hormone deficiency in people 3 to 17 years

Technology appraisal guidance

Published: 3 June 2025

www.nice.org.uk/guidance/ta1066

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme](#).

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations](#) wherever possible.

Contents

1 Recommendations	4
Why these recommendations were made	4
2 Information about somapacitan	6
Marketing authorisation indication	6
Dosage in the marketing authorisation	6
Price.....	6
Carbon Reduction Plan	7
3 Implementation.....	8
4 Evaluation committee members and NICE project team.....	9
Evaluation committee members	9
Chair	9
NICE project team	9

1 Recommendations

- 1.1 Somapacitan can be used, within its marketing authorisation, as an option to treat growth failure caused by growth hormone deficiency in people 3 to 17 years. Somapacitan can be used if the company provides it at the same price or lower than that agreed with the Medicines Procurement and Supply Chain, where applicable.
- 1.2 Use the least expensive option of the available treatments (including somapacitan and any preparation of somatropin). Take account of administration costs, dosages, price per dose and commercial arrangements. If the least expensive option is unsuitable, people with the condition and their healthcare professional should discuss the advantages and disadvantages of other treatments

What this means in practice

Somapacitan must be funded in the NHS in England for the condition and population in the recommendations, if it is considered the most suitable treatment option. Somapacitan must be funded in England within 30 days of final publication of this guidance.

There is enough evidence to show that somapacitan provides benefits and value for money, so it can be used routinely across the NHS in this population.

NICE has produced [tools and resources to support the implementation of this guidance](#).

Why these recommendations were made

For this evaluation, somapacitan was considered only for treating growth failure caused by growth hormone deficiency in people 3 to 17 years. This does not include everyone who it is licensed for.

Growth failure caused by growth hormone deficiency in people 3 to 17 years is usually

treated with somatogon or somatropin (available in multiple preparations). Somapacitan works in a similar way to these 2 treatments, and would be offered to the same population.

Clinical trial evidence shows that somapacitan works as well as somatropin.

The cost modelling used a range of dosages of somatropin that reflects the range used in the NHS. It also took into account the costs of somapacitan and somatropin in primary and secondary care. The cost comparison suggests that the cost of somapacitan is similar to or lower than the cost of somatropin. So somapacitan can be used.

For all evidence see the [committee papers](#). For more information on NICE's evaluation of somatropin, see the committee discussion section in [NICE's technology appraisal guidance on somatropin](#).

2 Information about somapacitan

Marketing authorisation indication

- 2.1 Somapacitan (Sogroya, Novo Nordisk) is indicated 'for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD)'.

Dosage in the marketing authorisation

- 2.2 The dosage schedule is available in the [summary of product characteristics for somapacitan](#).

Price

- 2.3 The list prices (excluding VAT; BNF online accessed February 2025) are:

- £285.45 per 1.5-ml vial containing 10 mg somapacitan
- £428.18 per 1.5-ml vial containing 15 mg somapacitan.

At the recommended dose of 0.16 mg/kg/week, the annual treatment cost for a person weighing 40 kg is £9,500.

- 2.4 The company has agreed a nationally available price reduction for somapacitan with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence.

Carbon Reduction Plan

- 2.5 For information, the Carbon Reduction Plan for UK carbon emissions is published in [Novo Nordisk's carbon reduction plan \(PDF\)](#).

3 Implementation

- 3.1 Section 7 of the [National Institute for Health and Care Excellence \(Constitution and Functions\)](#) and the [Health and Social Care Information Centre \(Functions\) Regulations 2013](#) requires integrated care boards, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 90 days of its date of publication. Because somapacitan has been recommended through the [cost-comparison process](#), NHS England and integrated care boards have agreed to provide funding to implement this guidance 30 days after publication.
- 3.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal guidance recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 60 days of the first publication of the final draft guidance.
- 3.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has growth failure caused by growth hormone deficiency and the doctor responsible for their care thinks that somapacitan is the right treatment, it should be available for use, in line with NICE's recommendations.

4 Evaluation committee members and NICE project team

Evaluation committee members

The highly specialised technologies evaluation committee is a standing advisory committee of NICE. This topic was considered as a cost comparison evaluation by the lead team of the highly specialised technologies evaluation committee, which includes the chair and vice chair.

Committee members are asked to declare any interests in the technology being evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

Chair

Paul Arundel

Chair, highly specialised technologies evaluation committee

NICE project team

Each technology appraisal is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.

Harsimran Sarpal

Technical lead

Lizzie Walker

Technical adviser

Leena Issa

Project manager

Ian Watson

Associate director

ISBN: 978-1-4731-7030-8